Selection of new TP53 mutations by therapy in chronic lymphocytic leukemia

Leukemia Research

Volumn 35, Issue 7, 2011, Pages 981-982

  Trbusek, Martin ^a   Malcikova, Jitka ^a   Mayer, Jiri ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Del(17p); Mutation; Selection; Therapy; TP53 p53

Indexed keywords

ANTINEOPLASTIC AGENT;

ALLELE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CHRONIC LYMPHATIC LEUKEMIA; DISEASE ACTIVITY; GENE MUTATION; GENETIC DISORDER; HUMAN; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; MUTATIONAL ANALYSIS; NOTE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; PROGNOSIS; REMISSION INDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79958737122     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.02.005     Document Type: Note

References (3)

1. Pekova S., Mazal O., Cmejla R., Hardekopf D.W., Plachy R., Zejskova L., et al. A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: analysis of 1287 diagnostic and 1148 follow-up CLL samples. Leuk Res 2011, 35:889-898.
2. Malcikova J., Smardova J., Rocnova L., Tichy B., Kuglik P., Vranova V., et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival and response to DNA damage. Blood 2009, 114:5307-5314.
3. Zenz T., Krober A., Scherer K., Habe S., Buhler A., Benner A., et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008, 112:3322-3329.